| 出版社 | QYResearch |
| 出版年月 | 2025年10月 |
Global Nucleic Acid Drugs Market Insights, Forecast to 2031
世界の核酸医薬品市場は、予測期間中に年平均成長率（CAGR）7.43%で成長し、2024年の1億4,636万米ドルから2031年には2億1,722万米ドルに達すると予測されています。
本レポートは、核酸医薬品の世界市場の概要と市場規模を概観しています。世界の市場動向を分析し、2020年～2024年の市場収益の過去データ、2025年の予測、そして2031年までのCAGR（年平均成長率）予測を提示しています。
本レポートでは、核酸医薬品の主要メーカーを調査し、主要地域および国の収益も提供しています。核酸医薬品の今後の市場ポテンシャル、そして市場を様々なセグメントおよびサブセグメントに分類するための主要地域/国についても重点的に分析しています。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国について、国別データと市場価値分析を提供しています。
このレポートでは、2020年から2031年までのセグメントデータをタイプ別、アプリケーション別、収益および成長率別に分析します。核酸医薬品の収益、予測される成長傾向、生産技術、アプリケーションおよびエンドユーザー産業の市場規模を評価および予測します。
Report Overview
The global Nucleic Acid Drugs market is projected to grow from US$ 14636 million in 2024 to US$ 21722 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.43% during the forecast period.
The North America market for Nucleic Acid Drugs is estimated to increase from $ 8327.53 million in 2024 to reach $ 11827 million by 2031, at a CAGR of 6.4% during the forecast period of 2025 through 2031.
The China market for Nucleic Acid Drugs is estimated to increase from $ 81.1 million in 2024 to reach $ 1231.84 million by 2031, at a CAGR of 44.83% during the forecast period of 2025 through 2031.
The Europe market for Nucleic Acid Drugs is estimated to increase from $ 3316.94 million in 2024 to reach $ 6063.24 million by 2031, at a CAGR of 10.64% during the forecast period of 2025 through 2031.
The global key companies of Nucleic Acid Drugs include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, etc. In 2024, the global top five players had a share approximately 86.47% in terms of revenue.
By Company
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- Novo Nordisk
- AstraZeneca
- Astellas Pharma
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies‘ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions